GLY 102
Alternative Names: GLY-102Latest Information Update: 09 Jul 2023
At a glance
- Originator Glycan Therapeutics
- Class
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Deep vein thrombosis
Most Recent Events
- 09 Jul 2023 Preclinical trials in Deep vein thrombosis (Prevention) in USA (unspecified route), prior to July 2023 (Glycan Therapeutics pipeline, July 2023)